Horizon Discovery (Horizon) today announced it has signed a commercial agreement with another major US Pharmceutical Company relating to the license of a panel of X-MAN™ cell-lines.
X-MAN ‘Mutant And Normal’ human isogenic cell-lines are the first genetically-defined in-vitro models of human cancer and their matched normal cell-types, that help accelerate and rationalize the discovery of novel ‘personalised’ medicines and their optimal assessment in clinical trials.
The agreement covers the ongoing license of a panel of eight X-MAN cell lines that represent model genotypes of interest to the Company.
“Chris Torrance, CEO of Horizon says “it is our aim to get our novel ‘patient-relevant’ X-MAN cancer models rapidly into the real world drug discovery arena and signing up another leading player and we hope to develop the relationship to include additional licenses and collaborations in the Rx and companion Dx space”.
The company who wish not to disclose the nature and scope of the agreement will pay Horizon undisclosed up-front and renewal fees under the agreement which will begin in July 2009.